Depemokimab Yields Sustained Asthma Benefits Over 2 Years
Summary
Depemokimab, an ultra long-acting biologic dosed twice a year, sustains its clinical benefits and safety profile over 2 years in patients with type 2 asthma with an eosinophilic phenotype.
Description from Medscape.
Who is covering this
-
Depemokimab Yields Sustained Asthma Benefits Over 2 Years
Depemokimab, an ultra long-acting biologic dosed twice a year, sustains its clinical benefits and safety profile over 2 years in patients with type 2 asthma with an eosinophilic phenotype.
Comments
Comments need JavaScript.